Nanobiotix receives approval from ANSM to start new Clinical Trial with Lead Product NBTXR3

barbara.lempert Second indication for NanoXray product in Head and Neck cancer patients Paris, France, June 13, 2013 – NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine ...

Eli Lilly racks up another Alzheimer’s failure after BACE drug sparks safety fears

John Carroll FierceBiotech News

Tweets of the day, 6/12/2013

chris.truelove by Christiane Truelove (chris.truelove@ubm.com) The big news today was Pfizer getting a $ 2.15B settlement from generics companies Teve and Sun over launches of generic ...

Tweets of the day, 6/11/2013

chris.truelove by Christiane Truelove (chris.truelove@ubm.com) As most people online lost their collective heads over the fact that the NSA is reading everything that they put out ...

Discovery Labs Presents Final Assessment in a Series of Pharmacoeconomic Analyses

barbara.lempert Discovery Labs Presents Final Assessment in a Series of Pharmacoeconomic Analyses that Explore Impact of Reintubation on Healthcare Costs Follow-up SURFAXIN® ...

Walgreens Pays $80M For Violating Controlled Substances Act

esilverman The latest manifestation over the nationwide effort to curb the widespread abuse of prescription painkillers has ensnared Walgreens. The largest US pharmacy chain ...

FDA warning letter cites Baxter for mold at plant, hair in infusion products

Eric Palmer The FDA has sent Baxter International a warning letter laying out problems it found during inspections at a plant in North Carolina as well as at a plant in Jayuya, Puerto ...

Agios selling $86M IPO to fund its first cancer drug trials

John Carroll FierceBiotech News

New deal part of Soriot’s revised strategy to energize AstraZeneca

Eric Palmer AstraZeneca's first-quarter earnings report was a stark indication of why its new CEO Pascal Soriot is scrambling to buy some new drugs the company can lean on. FiercePharma ...

Oncology Practices to Lose $250K Annually to Budget Sequester

mia.burns ZS Associates predicts long-term impact on community oncology practices EVANSTON, Ill. – June 5, 2013 – The budget sequester that went into effect in March reduced ...

Forest prepares to negotiate with investor Icahn on board positions

Emily Mullin Forest Laboratories faces another proxy battle as its annual investor meeting this summer looms. Icahn, the company's second largest shareholder, has been highly critical ...

Roche rejects option on autism drug from struggling Seaside

Ryan McBride Seaside Therapeutics has suffered a string of setbacks recently. Swiss drug giant Roche has passed on taking an option on Cambridge, MA-based Seaside's lead drug candidate ...
Page 30 of 118« First...1020...2829303132...405060...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS